Key points are not available for this paper at this time.
Design
Review
Mechanism-specific antiarrhythmics remain investigational; leaves open clinical translation pending prospective trials.
Cardiac arrhythmias complicate many diseases affecting the heart and circulation, and they incorporate a multiplicity of underlying mechanisms. The evolution of scientific knowledge has made the complex changes produced by cardiovascular disease sufficiently understood at the organ, cellular, and molecular levels such that there is a diversity of therapeutic targets for pharmacological therapy and/or prevention. Moreover, the approach of rational drug design in mechanism-specific and disease-specific fashions facilitates the targeting of therapy using the methods of molecular, structural, and translational biology. Additional approaches, using similar drug design strategies but based on gene therapy and transcriptional and translational modification, are on the horizon. Hence, there is reason to be optimistic regarding the design, testing, and clinical availability of novel antiarrhythmic therapies.
No takes yet. Share an insight, caveat, or question.
A 2001 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: